key: cord-0852830-mzfytn30
authors: Williamson, Gary; Kerimi, Asimina
title: Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction
date: 2020-06-25
journal: Biochem Pharmacol
DOI: 10.1016/j.bcp.2020.114123
sha: e8101b9d93cfefde48e94aeebc21ea203645ad5a
doc_id: 852830
cord_uid: mzfytn30

Commonly used drugs for treating many conditions are either natural products or derivatives. In silico modelling has identified several natural products including quercetin as potential highly effective disruptors of the initial infection process involving binding to the interface between the SARS-CoV-2 (Covid-19) Viral Spike Protein and the epithelial cell Angiotensin Converting Enzyme-2 (ACE2) protein. Here we argue that the oral route of administration of quercetin is unlikely to be effective in clinical trials owing to biotransformation during digestion, absorption and metabolism, but suggest that agents could be administered directly by alternative routes such as a nasal or throat spray.

The first disease-initiating interaction of the SARS-CoV-2 virus with the human organism at the molecular level is through binding of the Viral Spike Protein with ACE2 (angiotensin converting enzyme-2). ACE2 is an enzyme attached by a single tail to the outer cell membrane and is particularly highly expressed in the goblet and ciliated cells of the nasal cavity [1] . In silico modelling of the interaction between the SARS-CoV-2 Viral Spike Protein and ACE2 identified quercetin from a database of 8,000 small molecule candidates of known drugs, metabolites, and natural products as one of the top 5 most potent compounds for binding to the interface site and potentially disrupting the initiating infection process [2] ( Figure 1 ). In support of this hypothesis, quercetin was active against infection in a model of virus cell entry and also inhibited the 3C-like protease of SARS-CoV in vitro [3, 4] . Based on these findings, it has been suggested that quercetin be incorporated into trials against Covid-

A key aspect of the therapeutically successful action of any drug is delivery to the appropriate site of action. When targeting the interaction of the Virus Spike Protein with ACE2 on the surface of the epithelial cells, the proposed bioactive molecule must reach that site at a concentration sufficient to interfere with the interaction. Based on in silico modelling [2] where the energy of the interaction (Vina score) was ~ -30,500 J/mol, quercetin would theoretically give 50% inhibition (based on ΔG = -RT ln K a , where ΔG is the change in Gibbs free energy, R is the gas constant, T is the temperature, K a is the association constant; assumption here is that Vina score in silico ≈ ΔG) at a concentration of very approximately 7

M. This calculation serves to help estimate the dose that might be needed at the site of action. Quercetin is a plant-based naturally occurring flavonoid. Plants store quercetin 4 attached to sugars which substantially interfere with protein interactions [6] but are released in the human digestive tract. [7] The oral bioavailability of quercetin is very well understood [8] . Even after administration of a high oral dose of quercetin, the maximum concentration of the free aglycone in plasma is only in the low nM range [9] , several orders of magnitude lower than required based on the above calculation. Canonical drug-metabolising pathways [10] convert most of the quercetin to sulfate, glucuronide and methyl conjugates. The concentration at the necessary site of action would therefore not match or even approach that required for an effect even with very large doses. However, although oral administration of quercetin is unlikely to be effective in disrupting SARS-CoV-2 Viral Spike Protein/ACE2 interactions (Figure 2 ), other routes of delivery could be effective. A nasal spray containing quercetin in a suitable form could deliver the appropriate concentration directly in the active molecular form, i.e. free unconjugated quercetin. Any formulation could include agents to improve stability and solubility [11] .

For a solution of quercetin to be active, a target of at least three times the inhibition constant is reasonable at the site of interaction, i.e. ≥ 25 M (≥ 7.6 g/ml). A single 10 ml nasal dose would therefore need to contain only ~76 g of quercetin. Although the required effective dose of quercetin is contained, for example, in only ~ 0.06 g of fresh red onion (www.phenolexplorer.eu), eating even large amounts of onions would not be effective owing to the bioavailability issues raised above. These points highlight that if any clinical studies were to be conducted to harness the in silico and in vitro data, the delivery method of the bioactive molecule is of critical importance. The United States Food and Drug Administration has already approved oral doses of quercetin as safe for human consumption. Quercetin given nasally was effective in a rat model of allergic rhinitis [12] , and the safety of quercetin has 5 been favourably assessed [13] . Quercetin at high doses, like any other bioactive compound, could have potentially off-target effects. Following local application by a nasal spray the possibility exists that quercetin could be transported or diffuse to other tissues such as the lungs and blood. Previously found beneficial effects on cardiovascular health biomarkers after regular consumption of quercetin [14] could deliver an additional positive outcome.

Patients with pre-existing cardiometabolic syndromes such as hypertension are at increased risk during Covid-19 infection, and the protective effects of quercetin increases the justification for trials. However, pre-existing lung cancer could be incompatible with quercetin treatment due to the effects of quercetin on metabolic reprogramming of the cancer cells, although many of these effects have been reported to be beneficial [15, 16] . We have recently published a review which traces the history of research on quercetin and other flavonoids [17] . One study on Covid-19 and quercetin has so far been entered into www.clinicaltrials.gov (20 th June 2020), and the ready availability of quercetin and its low toxicity [13] supports the potential benefits of clinical trials on quercetin [5] .

We encourage researchers to consider bioavailability issues before embarking on an expensive clinical trial. Based on the evidence presented here, it could be possible that a nasal spray of dilute quercetin in a suitable vehicle, administered regularly at low doses during the early stages of infection, could attenuate entry of the virus into cells and so reduce the severity of the early stages of the infection, possibly leading to a reduced need for hospitalisation. We suggest that clinical trials should be conducted as soon as possible to test this. However, we emphasize that oral administration of even high doses of quercetin, either as a drug in pure form or in food, is unlikely to be successful owing to the known metabolism of quercetin, involving extensive conjugation and low plasma concentrations. The residues shown are redrawn for quercetin based on the interaction reported for the related flavonoid eriodictyol [2] . Amino acids in red belong to the spike protein and those in blue to ACE2. The structures of the two most abundant quercetin conjugates found in the blood after 7 oral consumption of quercetin [6, 7, 9] are shown to illustrate that the bulky attached moieties would preclude binding to the same site as quercetin. Quercetin-3-O-glucoside is also shown as the major form of quercetin in onions [19] before digestion, which has a bulky glucose moiety attached. The crystal structure between ACE2 and the viral spike protein has recently been refined [20] . 

SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways

Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?

Conjugation position of quercetin glucuronides and effect on biological activity, Free Rad

Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases

Bioavailability of quercetin in humans with a focus on interindividual variation

Flavonoid metabolites in human plasma and urine after the consumption of red onions: analysis by liquid chromatography with photodiode array and full scan tandem mass spectrometric detection

Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters

Improvement strategies for the oral bioavailability of poorly water-soluble flavonoids: An overview

Effectiveness of quercetin in an experimental rat model of allergic rhinitis

Safety aspects of the use of quercetin as a dietary supplement

Impact of flavonols on cardiometabolic bBiomarkers: A meta-analysis of randomized controlled human trials to explore the role of inter-individual variability

Differential impact of flavonoids on redox modulation, bioenergetics and cell signalling in normal and tumor cells: a comprehensive review

Dietary quercetin, quercetin-gene interaction, metabolic gene expression in lung tissue and lung cancer risk

The bioavailability, transport, and bioactivity of dietary flavonoids: A review from a historical perspective

ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: Demon or angel?

Analysis of the major flavonol glycosides present in four varieties of onion (Allium cepa) and changes in composition resulting from autolysis

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Authors' Contributions: Both authors contributed equally to writing the article and GW prepared the figures.Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Competing Interests statement: GW is an occasional consultant for Nutrilite, USA.